NCT03172494

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 720 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Conditions

• Diabetes
• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Insulin degludec/liraglutide	Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
DRUG	Insulin degludec	Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.
DRUG	Liraglutide	Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.

Timeline

• Start date: 2017-05-26
• Primary completion: 2019-06-14
• Completion: 2019-07-13
• First posted: 2017-06-01
• Last updated: 2022-12-14
• Results posted: 2020-07-07

Locations

36 sites across 1 country: China

Regulatory

• FDA-regulated drug study